Therapeutically, targeting the disrupted cell-cycle regulation by CDKN2A variants is explored through CDK4/6 inhibitors, showing promise in various cancers; although, the impact of CDKN2A status on treatment response requires further exploration [60]. This evidence concerns the gene CDKN2A and cancer.